Golimumab, compared to placebo, may be the drug that provides the highest probability of achieving ASAS20 response in AS patients naive to biologic treatments at 12 weeks. PubMed, Clin Drug Investig, 2014 Nov 12. (Also see: Biologic Agents)
This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.